IMS Health And Foundation Medicine, Inc. Announce Collaboration To Optimize Targeting Of Precision Therapies In Oncology

DANBURY, Conn. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMS Health (NYSE:IMS) and Foundation Medicine, Inc. (NASDAQ:FMI) today announced a collaboration to advance the understanding and effectiveness of precision medicines for treating cancer. Commercial, medical and outcomes research teams in biopharma and life sciences companies will now be able to leverage an offering that combines IMS Health’s powerful Real-World Evidence (RWE) platform providing clinical and cost-of-care insights with Foundation Medicine’s dynamic knowledgebase of comprehensive cancer genomic profiles, all at the patient-anonymous level.

Help employers find you! Check out all the jobs and post your resume.